TET2 and acute myocardial infarction: The increased mortality was mainly driven by a progression of heart failure, but not by the occurrence of acute ischemic events, because only 1 death was owing to a recurring acute myocardial infarction. In addition, impaired clinical outcome associated with DNMT3A and TET2 CHIP driver mutations was independent of the classical prognostic factors SHFM score and NT-proBNP serum levels, which are regarded as the most comprehensive markers of clinical outcome in CHF.